非侵入性癌症診斷：各種技術和全球市場

全球非侵入性癌症診斷市場規模預計將從 2025 年的 1,199 億美元成長到 2030 年底的 1,652 億美元，在 2025 年至 2030 年的預測期內，複合年成長率將達到 6.6%。

預計北美市場將從 2025 年的 486 億美元成長到 2030 年底的 685 億美元，在 2025 年至 2030 年的預測期內，複合年成長率將達到 7.1%。

預計歐洲市場將從 2025 年的 294 億美元成長到 2030 年底的 393 億美元，在 2025 年至 2030 年的預測期內，複合年成長率將達到 6%。

本報告考察了全球非侵入性癌症診斷市場和技術，提供了市場概述、市場影響因素和機會分析、技術和專利趨勢、法律制度、歷史和預測的市場規模、按各個細分市場和地區進行的詳細分析以及主要企業的概況。

目錄

第1章：執行摘要

• 市場展望
• 調查範圍
• 市場概況
• 市場動態與成長要素
• 新興技術
• 細分市場分析
• 區域分析
• 結論

第2章 市場概覽

• 當前市場概況
• 診斷影像技術
• 先進的非侵入性方法
• 常規癌症篩檢、診斷測試和檢查
• 波特五力分析
• 宏觀經濟因素分析
• 疾病負擔日益加重，診斷需求不斷增加
• 醫療費用支出和支付方趨勢
• 宏觀經濟成長與資金籌措環境
• 技術進步
• 美國關稅的影響

第3章 市場動態

• 概述
• 市場促進因素
• 癌症發生率增加
• 液態生物檢體技術的廣泛應用
• 轉向早期診斷和預防性診斷
• 醫療費用及研發經費增加
• 市場限制因素
• 先進診斷技術高成本
• 發展中地區意識水準低
• 市場機遇
• 人工智慧輔助診斷和數位病理學
• 新興市場人口缺乏足夠的篩檢服務。
• 市場挑戰
• 放射科醫生短缺
• 假陽性和假陰性結果

第4章 監管情勢

• 美國核准流程
• 歐盟核准流程
• 亞太地區核准流程
• 日本
• 中國
• 澳洲
• 印度

第5章 新興科技與發展

• 重點
• 多癌早期檢測 (MCED)
• 放射組學技術
• 利用尿液進行分子檢測
• 呼吸檢測儀診斷（揮發性有機化合物）
• 多體學學診斷平台
• 專利分析
• 主要發現

第6章 市場區隔分析

• 細分市場
• 市場分析：依癌症類型分類
• 重點
• 乳癌
• 肺癌
• 結腸癌
• 攝護腺癌
• 子宮頸癌
• 胃癌
• 肝癌
• 食道癌
• 膀胱癌
• 其他所有癌症
• 市場分析：依技術類型分類
• 重點
• 診斷影像技術
• 先進的非侵入性方法
• 常規非侵入性癌症篩檢、診斷檢測和測試
• 市場分析：依最終用戶分類
• 重點
• 醫院
• 學術機構
• 癌症研究所
• 診斷中心
• 政府和私人研究機構
• 製藥公司
• 製藥合約研究組織
• 按地區分類
• 市場分析：按地區分類
• 重點
• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第7章 競爭訊息

• 重點
• 全球非侵入性癌症診斷市場主要企業
• 主要發展和策略
• 夥伴關係與合作
• 獲得
• 關鍵策略活動和發展
• 產品上市及監管核准

第8章 全球非侵入性癌症診斷市場的永續性：ESG觀點

• ESG概覽
• 主要製造商：ESG舉措
• BCC的總結

第9章附錄

• 調查方法
• 簡稱
• 資訊來源
• 公司簡介
• ABBOTT
• BD
• BIO-RAD LABORATORIES INC.
• EXACT SCIENCES CORP.
• F. HOFFMANN-LA ROCHE LTD.
• GUARDANT HEALTH INC.
• HOLOGIC INC.
• ILLUMINA INC.
• KONINKLIJKE PHILIPS NV
• LABCORP
• LEICA BIOSYSTEMS NUSSLOCH GMBH
• QIAGEN
• REVVITY
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.
• 新興Start-Ups公司/市場顛覆者

The global market for noninvasive cancer diagnostic technologies is expected to grow from $119.9 billion in 2025 and is projected to reach $165.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.6% during the forecast period of 2025 to 2030.

The North American market for noninvasive cancer diagnostic technologies is expected to grow from $48.6 billion in 2025 and is projected to reach $68.5 billion by the end of 2030, at a CAGR of 7.1% during the forecast period of 2025 to 2030.

The European market for noninvasive cancer diagnostic technologies is expected to grow from $29.4 billion in 2025 and is projected to reach $39.3 billion by the end of 2030, at a CAGR of 6% during the forecast period of 2025 to 2030.

Report Scope

The report provides an overview of noninvasive cancer diagnostics technologies and global markets, with a detailed analysis of current market trends. It presents global revenue ($ Million) for the base year 2024, estimated data for 2025, and forecast data for 2026 through 2030. It also includes detailed insights into revenues, forecasts, product indications, and market segmentation. The market is segmented by cancer type, technologies, and end user. Regional coverage encompasses North America, Europe, the Asia-Pacific, and South Africa, with detailed analyses of the Middle East and Africa (MEA), including major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, and India.

This report provides a detailed overview of noninvasive cancer diagnostic products currently available in the market. It also examines cancer incidence and mortality statistics to provide context for market demand, outlines key challenges limiting the widespread adoption of these technologies, and highlights recent innovations shaping the next generation of diagnostic tools. It provides an in-depth overview of industry dynamics, including opportunities, constraints, and the competitive environment, highlighting both international leaders and smaller regional players active in the market.

The report offers a competitive landscape and includes information on major suppliers and manufacturers, describing their core products and strategic focus areas. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio, and recent developments in major companies.

Report Includes

• 71 data tables and 63 additional tables
• In-depth analysis of the global market for noninvasive cancer diagnostics and technologies
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by technology, cancer type, end user and region
• Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations and prospects, and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Review of next-generation novel noninvasive cancer molecular diagnostics platforms, current methods and future perspectives on early-stage cancer detection, and emerging biomarker technologies for diagnosis and treatment of cancer
• Evaluation of the current products, their indications and availability for all the market segments identified, and intended clinical applications
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Profiles of the leading global companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Labcorp Holdings Inc., and Abbott

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of the Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Current Market Overview
• Diagnostic Imaging Technologies
• Advanced Noninvasive Approaches
• Conventional Cancer Screening, Diagnostic Assays and Tests
• Porter's Five Forces Analysis
• Competitive Rivalry (High)
• Potential for New Entrant (Moderate to High)
• Threat of Substitutes (Moderate)
• Bargaining Power of Suppliers (Moderate)
• Bargaining Power of Buyers (Hospitals, Diagnostic Labs, Payers, and Patients) (High)
• Macroeconomic Factors Analysis
• Rising Disease Burden and Growing Demand for Diagnostics
• Healthcare Spending and Payer Dynamics
• Macroeconomic Growth and Funding Environment
• Technological Advances
• Impact of U.S. Tariffs

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Increasing Prevalence of Cancer
• Growing Adoption of Liquid Biopsy Technologies
• Shift Toward Early and Preventive Diagnosis
• Rising Healthcare Expenditure and R&D Funding
• Market Restraints
• High Cost of Advanced Diagnostic Technologies
• Low Awareness in Developing Regions
• Market Opportunities
• AI-Enabled Diagnostics and Digital Pathology
• Emerging Markets with Underserved Screening Populations
• Market Challenges
• Shortage of Radiologists
• False-Positive and False-Negative Results

Chapter 4 Regulatory Landscape

• U.S. Approval Process
• EU Approval Process
• Asia-Pacific Approval Process
• Japan
• China
• Australia
• India

Chapter 5 Emerging Technologiesand Developments

• Key Takeaways
• Multi-Cancer Early Detection (MCED) Tests
• Radiomics Technology
• Urine-Based Molecular Tests
• Breath-Based Diagnostics (Volatile Organic Compounds)
• Multi-Omics Diagnostic Platforms
• Patent Analysis
• Key Findings

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Market Analysis, by Cancer Type
• Key Takeaways
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Cervical Cancer
• Stomach Cancer
• Liver Cancer
• Esophageal Cancer
• Bladder Cancer
• All Other Cancers
• Market Analysis, by Technology Type
• Key Takeaways
• Diagnostic Imaging Technologies
• Advanced Noninvasive Approaches
• Conventional Noninvasive Cancer Screening, Diagnostic Assays and Tests
• Market Analysis, by End User
• Key Takeaways
• Hospitals
• Academic Institutes
• Cancer Institutes
• Diagnostic Centers
• Government and Private Research Institutes
• Pharmaceutical Companies
• Contract Research Organizations
• Geographic Breakdown
• Market Analysis, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Key Takeaways
• Leading Companies in Global Noninvasive Cancer Diagnostics Market
• Key Developments and Strategies
• Partnerships and Collaborations
• Acquisitions
• Key Strategic Activities and Developments
• Product Launches and Regulatory Approvals

Chapter 8 Sustainability in Global Noninvasive Cancer Diagnostics Market: An ESG Perspective

• Introduction to ESG
• Major Manufacturers: ESG Efforts
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBOTT
• BD
• BIO-RAD LABORATORIES INC.
• EXACT SCIENCES CORP.
• F. HOFFMANN-LA ROCHE LTD.
• GUARDANT HEALTH INC.
• HOLOGIC INC.
• ILLUMINA INC.
• KONINKLIJKE PHILIPS N.V.
• LABCORP
• LEICA BIOSYSTEMS NUSSLOCH GMBH
• QIAGEN
• REVVITY
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.
• Few Emerging Startups/Market Disruptors

List of Tables

• Summary Table : Global Market for Noninvasive Cancer Diagnostics, by Region, Through 2030
• Table 1 : Types of Liquid Biopsy and Their Clinical Applications, 2024
• Table 2 : Diagnostic Imaging Technologies in Noninvasive Cancer Diagnostics
• Table 3 : Advanced Technologies in Noninvasive Cancer Diagnostics
• Table 4 : Conventional Technologies in Noninvasive Cancer Diagnostics
• Table 5 : Porter's Five Forces Analysis: Rating Scale
• Table 6 : Estimated Cancer Incidence, Age (0-85+), 2022-2045
• Table 7 : Estimated Cancer Incidence in Males in the U.S., by Cancer Site, 2025
• Table 8 : Estimated Cancer Incidence in Females in the U.S., by Cancer Site, 2025
• Table 9 : Some FDA/CE-IVD Approved Liquid Biopsy Tests
• Table 10 : NCI Funding Across Cancer Research Areas, 2023
• Table 11 : Selected Published Patents for Noninvasive Cancer Diagnostics Technologies, October 2025
• Table 12 : Global Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
• Table 13 : Global Market for Noninvasive Breast Cancer Diagnostics, by Region, Through 2030
• Table 14 : Global Market for Noninvasive Lung Cancer Diagnostics, by Region, Through 2030
• Table 15 : Global Market for Noninvasive Colorectal Cancer Diagnostics, by Region,Through 2030
• Table 16 : Global Market for Noninvasive Prostate Cancer Diagnostics, by Region, Through 2030
• Table 17 : Global Market for Noninvasive Cervical Cancer Diagnostics, by Region, Through 2030
• Table 18 : Global Market for Noninvasive Stomach Cancer Diagnostics, by Region, Through 2030
• Table 19 : Global Market for Noninvasive Liver Cancer Diagnostics, by Region, Through 2030
• Table 20 : Global Market for Noninvasive Esophageal Cancer Diagnostics, by Region, Through 2030
• Table 21 : Global Market for Noninvasive Bladder Cancer Diagnostics, by Region, Through 2030
• Table 22 : Global Market for All Other Noninvasive Cancer Diagnostics, by Region, Through 2030
• Table 23 : Global Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 24 : Global Market for Noninvasive Cancer Diagnostic Imaging Technologies,by Region, Through 2030
• Table 25 : Global Market for Noninvasive Cancer Diagnostic Imaging Technologies, by Type, Through 2030
• Table 26 : Global Market for Advanced Noninvasive Approaches of Cancer Diagnostics, by Region, Through 2030
• Table 27 : Global Market for Advanced Noninvasive Approaches of Cancer Diagnostics, by Type, Through 2030
• Table 28 : Global Market for Conventional Noninvasive Cancer Screening, Diagnostic Assays and Tests, by Region, Through 2030
• Table 29 : Global Market for Conventional Noninvasive Cancer Screening, Diagnostic Assays and Tests, by Type, Through 2030
• Table 30 : Global Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
• Table 31 : Global Market for Noninvasive Cancer Diagnostics in Hospitals, by Region, Through 2030
• Table 32 : Global Market for Noninvasive Cancer Diagnostics in Academic Institutes, by Region, Through 2030
• Table 33 : Global Market for Noninvasive Cancer Diagnostics in Cancer Institutes, by Region, Through 2030
• Table 34 : Global Market for Noninvasive Cancer Diagnostics in Diagnostic Centers, by Region, Through 2030
• Table 35 : Global Market for Noninvasive Cancer Diagnostics in Government and Private Research Institutes, by Region, Through 2030
• Table 36 : Global Market for Noninvasive Cancer Diagnostics in Pharmaceutical Companies, by Region, Through 2030
• Table 37 : Global Market for Noninvasive Cancer Diagnostics in Contract Research Organizations, by Region, Through 2030
• Table 38 : Global Market for Noninvasive Cancer Diagnostics, by Region, Through 2030
• Table 39 : North American Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
• Table 40 : North American Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 41 : North American Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
• Table 42 : North American Market for Noninvasive Cancer Diagnostics, by Country, Through 2030
• Table 43 : U.S. Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 44 : Canadian Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 45 : Mexican Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 46 : European Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
• Table 47 : European Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 48 : European Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
• Table 49 : European Market for Noninvasive Cancer Diagnostics, by Country, Through 2030
• Table 50 : German Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 51 : U.K. Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 52 : French Market for Noninvasive Cancer Diagnostics, by Technology Type,Through 2030
• Table 53 : Italian Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 54 : Spanish Market for Noninvasive Cancer Diagnostics, by Technology Type,Through 2030
• Table 55 : Rest of Europe Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 56 : Asia-Pacific Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
• Table 57 : Asia-Pacific Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 58 : Asia-Pacific Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
• Table 59 : Asia-Pacific Market for Noninvasive Cancer Diagnostics, by Country, Through 2030
• Table 60 : Chinese Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 61 : Indian Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 62 : Japanese Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 63 : South Korean Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 64 : Rest of Asia-Pacific Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 65 : South American Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
• Table 66 : South American Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 67 : South American Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
• Table 68 : MEA Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
• Table 69 : MEA Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
• Table 70 : MEA Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
• Table 71 : Leading Manufacturers and Service Providers in the Global Noninvasive Cancer Diagnostics Market, 2024
• Table 72 : Collaboration and Partnership in Global Noninvasive Cancer Diagnostics Market, 2023-2025
• Table 73 : Acquisitions in Global Noninvasive Cancer Diagnostics Market, 2023-2025
• Table 74 : Key Strategic Activities and Developments in Global Noninvasive Cancer Diagnostics Market, 2024-2025
• Table 75 : Product Launches and Regulatory Approval in Global Noninvasive Cancer Diagnostics Market, 2023-2025
• Table 76 : ESG Highlights, by Major Players, 2024
• Table 77 : Abbreviations Used in This Report
• Table 78 : Report Information Sources
• Table 79 : Abbott: Company Snapshot
• Table 80 : Abbott: Financial Performance, FY 2023 and 2024
• Table 81 : Abbott: Product Portfolio
• Table 82 : Abbott: News/Key Developments, 2023-2025
• Table 83 : BD: Company Snapshot
• Table 84 : BD: Financial Performance, FY 2024 and 2025
• Table 85 : BD: Product Portfolio
• Table 86 : BD: News/Key Developments, 2023-2025
• Table 87 : Bio-Rad Laboratories Inc.: Company Snapshot
• Table 88 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
• Table 89 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 90 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024-2025
• Table 91 : Exact Sciences Corp.: Company Snapshot
• Table 92 : Exact Sciences Corp.: Financial Performance, FY 2023 and 2024
• Table 93 : Exact Sciences Corp.: Product Portfolio
• Table 94 : Exact Sciences Corp.: News/Key Developments, 2023-2025
• Table 95 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 96 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 97 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 98 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2025
• Table 99 : Guardant Health Inc.: Company Snapshot
• Table 100 : Guardant Health Inc.: Financial Performance, FY 2023 and 2024
• Table 101 : Guardant Health Inc.: Product Portfolio
• Table 102 : Guardant Health Inc.: News/Key Developments, 2024-2025
• Table 103 : Hologic Inc.: Company Snapshot
• Table 104 : Hologic Inc.: Financial Performance, FY 2024 and 2025
• Table 105 : Hologic Inc.: Product Portfolio
• Table 106 : Hologic Inc.: News/Key Developments, 2023-2025
• Table 107 : Illumina Inc.: Company Snapshot
• Table 108 : Illumina Inc.: Financial Performance, FY 2023 and 2024
• Table 109 : Illumina Inc.: Product Portfolio
• Table 110 : Illumina Inc.: News/Key Developments, 2023-2025
• Table 111 : Koninklijke Philips N.V.: Company Snapshot
• Table 112 : Koninklijke Philips N.V.: Financial Performance, FY 2023 and 2024
• Table 113 : Koninklijke Philips N.V.: Product Portfolio
• Table 114 : Koninklijke Philips N.V.: News/Key Developments, 2024-2025
• Table 115 : Labcorp: Company Snapshot
• Table 116 : Labcorp: Financial Performance, FY 2023 and 2024
• Table 117 : Labcorp: Product Portfolio
• Table 118 : Labcorp: News/Key Developments, 2023-2025
• Table 119 : Leica Biosystems Nussloch GmbH.: Company Snapshot
• Table 120 : Leica Biosystems Nussloch GmbH.: Product Portfolio
• Table 121 : Leica Biosystems Nussloch GmbH.: News/Key Developments, 2024-2025
• Table 122 : QIAGEN: Company Snapshot
• Table 123 : QIAGEN: Financial Performance, FY 2023 and 2024
• Table 124 : QIAGEN: Product Portfolio
• Table 125 : QIAGEN: News/Key Developments, 2024-2025
• Table 126 : Revvity: Company Snapshot
• Table 127 : Revvity: Financial Performance, FY 2023 and 2024
• Table 128 : Revvity: Product Portfolio
• Table 129 : Revvity: News/Key Developments, 2023-2025
• Table 130 : Siemens Healthineers AG: Company Snapshot
• Table 131 : Siemens Healthineers AG: Financial Performance, FY 2024 and 2025
• Table 132 : Siemens Healthineers AG: Product Portfolio
• Table 133 : Siemens Healthineers AG: Key Developments, 2024-2025
• Table 134 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 135 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
• Table 136 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 137 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023-2025
• Table 138 : List of a Few Emerging Startups/Market Disruptors

List of Figures

• Summary Figure : Global Market Shares for Noninvasive Cancer Diagnostics, by Region, 2024
• Figure 1 : Market Dynamics of Noninvasive Cancer Diagnostics
• Figure 2 : Number of Patents for Noninvasive Cancer Diagnostics, by Leading Applicants, January 2025-October 2025
• Figure 3 : Patent Shares for Noninvasive Cancer Diagnostics, by Jurisdiction, January 2025-October 2025
• Figure 4 : Patent Shares for Noninvasive Cancer Diagnostics, by Type, January 2025-October 2025
• Figure 5 : Global Market Shares for Noninvasive Cancer Diagnostics, by Cancer Type, 2024
• Figure 6 : Global Market Shares for Noninvasive Cancer Diagnostics, by Technology Type, 2024
• Figure 7 : Global Market Shares for Noninvasive Cancer Diagnostics, by End User, 2024
• Figure 8 : Global Market Shares for Noninvasive Cancer Diagnostics, by Region, 2024
• Figure 9 : Global Market Shares for Noninvasive Cancer Diagnostics, by Company, 2024
• Figure 10 : Pillars of Sustainable Cancer Care
• Figure 11 : Abbott: Revenue Share, by Business Unit, FY 2024
• Figure 12 : Abbott: Revenue Share, by Country/Region, FY 2024
• Figure 13 : BD: Revenue Share, by Business Unit, FY 2025
• Figure 14 : BD: Revenue Share, by Country/Region, FY 2025
• Figure 15 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 16 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 17 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2024
• Figure 18 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2024
• Figure 19 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 20 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 21 : Guardant Health Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 22 : Guardant Health Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 23 : Hologic Inc.: Revenue Share, by Business Unit, FY 2025
• Figure 24 : Hologic Inc.: Revenue Share, by Country/Region, FY 2025
• Figure 25 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 26 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 27 : Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2024
• Figure 28 : Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2024
• Figure 29 : Labcorp: Revenue Share, by Business Unit, FY 2024
• Figure 30 : Labcorp: Revenue Share, by Country/Region, FY 2024
• Figure 31 : QIAGEN: Revenue Share, by Business Unit, FY 2024
• Figure 32 : QIAGEN: Revenue Share, by Country/Region, FY 2024
• Figure 33 : Revvity: Revenue Share, by Business Unit, FY 2024
• Figure 34 : Revvity: Revenue Share, by Country/Region, FY 2024
• Figure 35 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2025
• Figure 36 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2025
• Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 38 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024